Clinical Trial Update: A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study evaluating low-dose adjuvant ipilimumab plus nivolumab after surgical resection of melanoma macrometastases; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Stage IIIC Skin Melanoma, Stage IV Skin Melanoma | Phase 1, Phase 2 | Status: COMPLETED